Sign In
Buy SNANF
$0.211
+0.0055 (+2.68%)
At Close: Jun 02, 2026
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
08:23am, Monday, 16'th Jun 2025
First Patients Expected to be Enrolled This Month Halifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused lif
Sona Nanotech on a mission to make cancer treatment more effective with fewer side effects
12:27pm, Monday, 02'nd Jun 2025
Cancer is an oftentimes fatal condition that has touched most people's lives directly or indirectly. And while there are treatments available, depending on the type of cancer in question and how advan
Sona Nanotech hits milestone in human trial readiness - ICYMI
04:00pm, Friday, 30'th May 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about a major regulatory milestone achieved by the company's golden nanorod therapy platform. The company announced that
Sona Nanotech advances cancer therapy program with positive preclinical study results
09:12am, Tuesday, 27'th May 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced positive results from a preclinical safety study evaluating the toxicity of its proprietary gold nanorods, fulfilling a prerequisite required b
Sona Successfully Completes FDA-Required Toxicity Study
08:27am, Tuesday, 27'th May 2025
Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety
Sona Nanotech advances toward first-in-human gold nanorod trial - ICYMI
12:11pm, Saturday, 24'th May 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) chief medical officer Dr Carman Giacomantonio joined Proactive to discuss a critical development in the company's gold nanorod cancer therapy. Dr Giacomantoni
Sona Nanotech completes endotoxin testing ahead of human study
10:03am, Thursday, 15'th May 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said it has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods, marking a key step ahead of the company's first-in-human ea
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
09:32am, Thursday, 15'th May 2025
Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin te
Sona Nanotech teams with BioVaxys on cancer tech – ICYMI
04:55pm, Friday, 09'th May 2025
Sona Nanotech Inc earlier this week announced a research collaboration with BioVaxys to explore potential synergy between their respective cancer therapy technologies. The company said the agreement w
Sona Nanotech and BioVaxys partner to develop novel cancer therapy
09:36am, Wednesday, 07'th May 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is joining forces with BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) to explore a new approach to cancer treatment. The two companies are collaborating on
BioVaxys and Sona Nanotech Enter Research Collaboration
09:12am, Wednesday, 07'th May 2025
Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA)
BioVaxys and Sona Nanotech Enter Research Collaboration
08:00am, Wednesday, 07'th May 2025
VANCOUVER, BC and HALIFAX, NS , May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") annou
Sona Nanotech Announces Annual Options Grants
09:21am, Thursday, 01'st May 2025
Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under th
Sona Nanotech chief medical officer talks latest targeted hyperthermia therapy findings - ICYMI
01:49pm, Saturday, 29'th Mar 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) chief medical officer Dr Carman Giacomantonio talked with Proactive about the company's latest findings related to its targeted hyperthermia therapy (THT), w
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025
12:17pm, Friday, 21'st Mar 2025
From potential changes in government healthcare policies to persistent inflationary pressures and evolving investment strategies, the US healthcare sector is facing a convergence of economic, regulato
